Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2012 - 2026)

Agios Pharmaceuticals has reported Change in Accured Expenses for 15 years, with the latest figure at -$19.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 26.57% year-over-year to -$19.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 166.35% YoY), and the FY2025 full-year result was -$1.4 million, down 407.97% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$19.2 million, down from $8.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $14.5 million in Q2 2025, with the low at -$26.1 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$1.2 million across 5 years, with a median of $1.4 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 1244.17% — and 2024, when it sank 364.03%.
• Agios Pharmaceuticals' Change in Accured Expenses stood at $5.2 million in 2022, then tumbled by 143.4% to -$2.3 million in 2023, then soared by 523.51% to $9.6 million in 2024, then declined by 14.0% to $8.2 million in 2025, then plunged by 332.54% to -$19.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$19.2 million (Q1 2026), $8.2 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.